Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Gera
Clinical trial register · Germany

Clinical Trials in Gera, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5062 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:18 UTC
5062
Studies in scope
all four open statuses
2869
Recruiting now
open to new participants
983
Lead sponsors
across recruiting studies
Top sites
Berlin 1587 Hamburg 893 Essen 765 Dresden 714 Heidelberg 626
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC5 BioNTech SE3 AstraZeneca2 Theravance Biopharma1 MED-EL Elektromedizinische Geräte GmbH1 Sanofi1 Hoffmann-La Roche1 Takeda1 APrevent Biotech GmbH1 Fondazione Michelangelo1 Biotronik SE & Co. KG1 Ipsen1 Abbott Medical Devices1 Bristol-Myers Squibb1 Gilead Sciences1 Daiichi Sankyo1 Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD1 Eli Lilly and Company1 EMD Serono Research & Development Institute, Inc.1
Site location
Berlin1587 Hamburg893 Essen765 Dresden714 Heidelberg626 Cologne619 Leipzig513 München510 Hanover487 Tübingen454 Bonn422 Düsseldorf409 Munich398 Freiburg im Breisgau394 Erlangen374 Frankfurt369 Münster359 Frankfurt am Main343 Ulm343 Mainz336 Würzburg296 Aachen266 Augsburg248 Kiel234 Lübeck225 Show all 638
All 638 locations
Target enrolment
to

Trials with a site in Gera

26 of 5062 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
AstraZeneca
Phase 3
4,500
Bad Oeynhausen, Bochum, Cologne, Dresden, Falkensee, Gera, Hamburg, Leipzig
2026-06-29
Recruiting
Biotronik SE & Co. KG
Observational
151
Würzburg, Gera
2026-06-22
Recruiting
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Phase 3
320
Berlin, Bonn, Gera, Göttingen, Halle, Karlsruhe, Recklinghausen, Rostock
2026-06-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
Heidelberg, Bochum, Mainz, Gera
2026-05-04
Recruiting
BioNTech SE
Phase 3
558
Augsburg, Braunschweig, Bremen, Frankfurt, Freiburg im Breisgau, Gera, Hamburg, Koblenz
2025-10-30
Recruiting
BioNTech SE
Phase 3
621
Berlin, Bonn, Chemnitz, Esslingen am Neckar, Gauting, Gera, Großhansdorf, Halle
2025-02-03
Recruiting
BioNTech SE
Phase 2/3
1,580
Aachen, Berlin, Chemnitz, Düsseldorf, Erlangen, Esslingen am Neckar, Gauting, Gera
2025-01-07
Active, closed
Ipsen
Phase 2
670
Berlin, Dresden, Essen, Frankfurt, Gera, Göppingen, Greifswald, Ulm
2024-10-10
Active, closed
Takeda
Phase 3
2,099
Blankenfelde-Mahlow, Bad Bentheim, Oldenburg, Dresden, Gera, Hamburg
2024-09-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Dortmund, Essen, Lübeck, Gera, Berlin
2024-06-10
Recruiting
Daiichi Sankyo
Phase 3
540
Berlin, Erfurt, Essen, Frankfurt, Frankfurt am Main, Gauting, Gera, Giessen
2024-05-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Erlangen, München, Potsdam, Georgsmarienhütte, Düsseldorf, Essen, Saarbrücken, Gera
2024-04-14
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Esslingen am Neckar, Regensburg, Hemer, Koblenz, Leipzig, Halle, Bad Berka, Gera
2024-04-03
Active, closed
MED-EL Elektromedizinische Geräte GmbH
Not applicable
20
Stuttgart, Würzburg, Gera, Berlin
2023-07-27
Active, closed
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT05696717Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
Theravance Biopharma
Phase 3
102
Gera, Berlin
2023-06-27
Active, closed
Gilead Sciences
Phase 3
654
Baden-Württemberg, Bayern, Berlin, Bottrop, Erlangen, Gera, Hamburg, Hanover
2023-05-08
Active, closed
Sanofi
Phase 2/3
1,856
Augsburg, Bad Bentheim, Berlin, Blankenfelde-Mahlow, Dresden, Frankfurt, Gera, Hamburg
2022-08-22
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Heidelberg, Immenhausen, Hanover, Großhansdorf, Gera
2022-03-24
Recruiting
APrevent Biotech GmbH
Not applicable
30
Gera, Hamburg
2019-11-13
Active, closed
Bristol-Myers Squibb
Phase 3
790
München, Bonn, Buxtehude, Dresden, Essen, Gera, Göttingen, Hanover
2019-10-28
Recruiting
Abbott Medical Devices
Observational
2,000
Tübingen, Ingolstadt, Cologne, Duisburg, Düsseldorf, Mönchengladbach, Lübeck, Gera
2019-03-13
Active, closed
Hoffmann-La Roche
Phase 3
1,000
Ulm, Regensburg, Lübeck, Essen, Freiburg im Breisgau, Gauting, Gera, Immenhausen
2019-02-28
Active, closed
Fondazione Michelangelo
Phase 3
650
Berlin, Bottrop, Coburg, Dortmund, Dresden, Frankfurt, Gera, Greifswald
2018-09-07
Active, closed
AstraZeneca
Phase 3
987
Aachen, Berlin, Gauting, Gera, Hamburg, Heidelberg, Mainz, Regensburg
2017-03-27
Active, closed
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
DrugTepotinib
EMD Serono Research & Development Institute, Inc.
Phase 2
337
Leipzig, Berlin, Chemnitz, Dresden, Erfurt, Gauting, Gera, Göttingen
2016-09-13
Active, closed
Eli Lilly and Company
Phase 3
453
Berlin, Gera, Großhansdorf, Hamburg, Hanover, Heidelberg, Immenhausen, Nuremberg
2014-10-03
Rows per page Showing 1–26 of 26
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 November 2026. https://priyalifescience.com/clinical-trials-germany/city/gera

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,062 studies in total at the last sync on 10 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 26 of those studies with a site in Gera.

How many clinical trials are recruiting in Gera?

13 of the 26 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Gera), 26 studies
PhaseStudiesRecruitingShare
Phase 318969.2%
Not applicable217.7%
Observational227.7%
Phase 2207.7%
Phase 2/3217.7%

Most active sponsors

Lead sponsors with the most studies (Gera)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC54
BioNTech SE33
AstraZeneca21
Abbott Medical Devices11
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD11
APrevent Biotech GmbH11
Biotronik SE & Co. KG11
Bristol-Myers Squibb10
Daiichi Sankyo11
Eli Lilly and Company10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.